On this page
Key takeaways
• Murray 2025 (Aging Cell) is the load-bearing paper — intermittent fisetin preserved muscle function in 24-month-old mice with effect sizes equivalent to genetic clearance of p16-positive cells and to ABT-263 (1).
• Head-to-head equivalence with gold-standard senolytic interventions is unusual for a natural compound and represents the strongest recent preclinical case in the fisetin field.
• Three human trials are actively testing muscle-function endpoints: AFFIRM in post-menopausal women (3), PROFFi in breast cancer survivors (4), and Fisetin HIGH in healthy volunteers and multimorbid older adults (5).
• No published human RCT has yet reported fisetin’s effect on grip strength, gait speed, or other frailty measures. AFFIRM has been unreported since 2018 (3).
• Senescent cell accumulation in skeletal muscle is a documented driver of sarcopenia (2,7). The mechanistic case is coherent.
• Resistance training remains the highest-evidence intervention for muscle preservation. Fisetin is a plausible adjunct, not a replacement.
Quick answer
Fisetin’s case for muscle preservation and frailty is the strongest recent preclinical case in the entire fisetin field. Murray and colleagues (Aging Cell, 2025) reported that intermittent fisetin dosing in 24-month-old mice preserved grip strength, gait speed, and muscle fibre integrity with effect sizes statistically indistinguishable from genetic clearance of p16-positive cells and from ABT-263, the pharmaceutical BCL-xL senolytic (1). Head-to-head equivalence with gold-standard senolytic interventions is striking. Three human trials are actively testing this hypothesis: AFFIRM (post-menopausal frail women), PROFFi (breast cancer survivors), and Fisetin HIGH (multimorbid older adults). None have reported. When AFFIRM publishes, the muscle-preservation case will move from preclinical hypothesis to clinically validated (or refuted) intervention. Resistance training remains the load-bearing intervention for muscle preservation with the strongest existing evidence. For the full context, see our complete clinician’s guide.
The Murray 2025 paper — fisetin equivalent to genetic senescent-cell clearance
Murray and colleagues (Aging Cell, 2025) is the most consequential preclinical fisetin paper since Yousefzadeh 2018 (1). The design directly compared fisetin against gold-standard interventions in aged mice — an experimental architecture that produces unusually informative results.
The comparators
Twenty-four-month-old mice — the human equivalent of roughly 70 years of age — were randomised to four arms:
• Vehicle control (untreated).
• Intermittent fisetin at doses equivalent to the human 20 mg/kg pulsed protocol.
• INK-ATTAC genetic clearance of p16-positive cells — the gold-standard preclinical intervention using an engineered mouse model.
• ABT-263 (navitoclax) — the pharmaceutical BCL-xL senolytic used in cancer trials.
The endpoints
Physical function endpoints (grip strength, gait speed, rotarod performance), skeletal muscle senescent cell markers (p16, p21, SA-β-gal), muscle fibre integrity by histology, and biochemical markers of muscle inflammation and regeneration.
The result
Fisetin preserved grip strength and gait speed with effect sizes statistically indistinguishable from both INK-ATTAC genetic clearance and ABT-263. Muscle senescent cell markers were reduced. Muscle fibre integrity was preserved. The three interventions — a natural flavonoid, a genetic clearance model, and a pharmaceutical senolytic — produced effectively the same functional and biochemical outcome.
This is unusual. Head-to-head equivalence between a natural compound and gold-standard preclinical interventions is rarely reported. Most natural compounds show effect sizes 20–80% smaller than their pharmaceutical or genetic comparators. Murray 2025 is the paper that made fisetin’s claim to clinical relevance in the muscle-preservation space credible to the geroscience field.
The senescent cell / sarcopenia connection
Sarcopenia — the age-related loss of muscle mass, strength, and function — is a major driver of frailty and disability in older adults (7). Its underlying biology is multifactorial: reduced protein synthesis, mitochondrial dysfunction, neuromuscular junction degradation, and — relevant here — accumulation of senescent cells in muscle tissue.
Senescent cells in skeletal muscle secrete SASP factors that impair satellite-cell function (satellite cells are the muscle stem cells responsible for repair and regeneration). This creates a self-reinforcing cycle: senescent cells damage the regenerative capacity of surrounding tissue, which accelerates further senescent-cell accumulation. Clearing senescent cells breaks this cycle, which is why senolytic interventions have consistently shown muscle-function benefits in preclinical models. Xu 2018 established this principle in mice using D+Q (2). Murray 2025 extended it to fisetin specifically (1).
The theoretical framework predicts that senolytic interventions should produce their most measurable benefits in the muscle-and-frailty space. This is what Murray 2025 shows. If AFFIRM confirms this in humans, muscle preservation and frailty prevention will be the flagship human clinical indication for fisetin.
The pending human trial pipeline
Three human trials are actively testing muscle-function endpoints with fisetin. All use variants of the pulsed protocol used in Murray 2025.
|
Trial (NCT) |
Population |
Primary endpoint |
Status |
|
AFFIRM (NCT03430037) (3) |
Post-menopausal frail women |
Adipose senescent-cell burden, physical function |
Running since 2018; unreported |
|
PROFFi (NCT06113016) (4) |
Breast cancer survivors |
Frailty prevention, muscle function |
Recruiting |
|
Fisetin HIGH (NCT06431932) (5) |
Healthy volunteers + multimorbid older adults |
PK, safety, functional endpoints |
Recruiting from March 2026 |
Why AFFIRM matters most
AFFIRM is the Phase 2, double-blind, placebo-controlled trial specifically designed to test whether the pulsed protocol reduces senescent-cell burden and preserves physical function in frail post-menopausal women. Its unreported status since 2018 is the single most consequential gap in the current fisetin literature. When AFFIRM publishes, one of three things will happen: (1) it confirms the Murray 2025 muscle-preservation result in humans, which would move fisetin from Tier 3 to Tier 2 evidence and reshape the entire longevity-supplement landscape; (2) it fails to demonstrate benefit, which would substantially undermine the human translation case despite the preclinical strength; or (3) it produces mixed or intermediate results that require follow-up trials to interpret. All three outcomes are consequential.
The dose translation — mouse to human
Murray 2025 used mouse doses that translate, by body-surface-area conversion, to roughly the human 20 mg/kg pulsed protocol used in the Mayo Clinic trials. For a 70 kg adult this is approximately 1,400 mg on day 1 and 1,400 mg on day 2, then no fisetin for 28 days. Approximately 12 pulses per year. See our dedicated pulse dosing article for the schedule detail.
The bioavailability caveat applies here as elsewhere. Unformulated oral fisetin produces plasma concentrations well below the in vitro senolytic window (9). Whether human tissue can reach senolytic concentrations in muscle at this dose is genuinely uncertain and is one of the things AFFIRM will test.
Practical guidance for readers
For readers specifically interested in muscle preservation and frailty prevention:
• Resistance training remains the highest-evidence intervention — twice weekly, progressive load, focused on major muscle groups. No supplement replaces this.
• Adequate protein intake (1.2–1.6 g/kg/day for older adults) supports muscle preservation independent of any supplement.
• If you want to include fisetin, use the pulsed protocol (20 mg/kg × 2 days, monthly). This aligns with the Murray 2025 architecture and every ongoing human trial.
• Track home functional measures — grip strength dynamometry, sit-to-stand tests, and gait speed — to see whether any measurable functional benefit accrues. These are the same measures the trials are using.
• Consider urolithin A as complementary — it has published RCT evidence for muscle strength improvement in middle-aged and older adults [c:2 in the vs-urolithin article]. The two compounds target different aspects of muscle ageing. See our fisetin vs urolithin A article.
What we still don't know
• Whether the Murray 2025 mouse result translates to humans. AFFIRM and PROFFi will begin to answer this.
• Whether the pulsed protocol produces cumulative benefit over years or hits a ceiling as resistant senescent-cell populations expand.
• Whether combining fisetin with resistance training is additive. Preclinical models suggest yes, but human data are absent.
• Whether specific patient subgroups respond differently — sex, baseline frailty, sarcopenic vs pre-sarcopenic muscle status. Not directly tested.
• Whether fisetin’s muscle-preservation effect is meaningful in already-frail patients or requires earlier intervention. AFFIRM enrols frail women specifically; PROFFi enrols pre-frail cancer survivors.
Bottom line
Muscle preservation and frailty prevention is the strongest recent preclinical case in the fisetin field. Murray 2025 demonstrated equivalent effects to gold-standard senolytic interventions in aged mice — an unusual result for a natural compound and a genuine argument for the biology. Three human trials are testing whether this translates to human clinical benefit. Until they report, the case is preclinically strong and clinically pending. Resistance training and adequate protein intake remain the highest-evidence muscle-preservation interventions. Fisetin is a plausible adjunct on the pulsed protocol; it is not a replacement for exercise-based approaches. When AFFIRM publishes, this article will be the first to be revised. For the full context, see our complete clinician’s guide and dedicated senolytic article.
Frequently asked questions
Does fisetin build muscle?
No. Fisetin does not stimulate muscle protein synthesis or promote hypertrophy. Its role is preservation of muscle function via senolytic clearance, not muscle building. Resistance training remains the intervention for muscle building.
Can fisetin reverse sarcopenia?
Preclinically in aged mice, yes — the Murray 2025 paper reported improved grip strength and gait speed with fisetin (1). In humans, this is pending trial validation.
Should older adults take fisetin?
Preclinically, older adults are the population most likely to benefit from senolytic intervention. Human trial validation is pending. The COVID-FIS trial in nursing home residents showed favourable safety in this population (8).
Is fisetin better than urolithin A for muscle?
Currently, urolithin A has the stronger human RCT evidence for muscle strength and endurance improvements in middle-aged and older adults. Fisetin has the stronger recent preclinical case. See our fisetin vs urolithin A article.
Can I take fisetin while I strength train?
Yes. No documented interaction between fisetin and exercise. Combined use is theoretically synergistic — both address muscle preservation through different mechanisms.
References
1. Murray KO, Mahoney SA, Venturini S, et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging. Aging Cell. 2025;24:e70114. https://doi.org/10.1111/acel.70114
2. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. https://pubmed.ncbi.nlm.nih.gov/29988130/
3. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037
4. PROFFi: Prevention of Frailty with Fisetin and Exercise in Breast Cancer Survivors (NCT06113016). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06113016
5. Pilot Trial of Fisetin in Healthy Volunteers and Older Patients with Multimorbidity — Fisetin HIGH (NCT06431932). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06431932
6. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
7. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. https://pubmed.ncbi.nlm.nih.gov/30312372/
8. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. https://pubmed.ncbi.nlm.nih.gov/30616998/
9. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72